Why did this ASX 300 cannabis share just rocket 12%?

Incannex is going to make its own pharmaceutical-grade psilocybin drug for clinical trials and potential commercial use.

| More on:
A graphic showing a rising share price in medical cannabis shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex has announced it is going to develop and manufacture its own cGMP-grade psilocybin drug for clinical trials
  • Incannex's chief scientific officer says the drug 'has the potential to help millions of people' who suffer from anxiety 
  • The ASX 300 cannabis share is soaring today, up 12% 

ASX 300 cannabis share Incannex Healthcare Ltd (ASX: IHL) is soaring today after the company announced some positive news.

The Incannex share price is currently 14 cents, up 11.54% for the day so far.

Let's see what's happening.

What news pushed this ASX 300 cannabis share higher?

Incannex is a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for conditions including generalised anxiety disorder.

Today, Incannex announced it is going to develop and manufacture its own cGMP-grade psilocybin drug for clinical trials.

In a statement, Incannex CEO Joel Latham said:

Having our own source of pharmaceutical grade psilocybin not only allows our company to freely undertake clinical trials, it also creates and assists with number of commercial opportunities which are currently at an advanced stage of investigation by the company, and will be announced in the coming weeks, following board appraisal and approval.

Incannex has engaged Catalent to develop the formulation.

The company said the manufacturing process would be designed so that it can be scaled up to commercial supply levels when appropriate.

'Potential to help millions of people'

Incannex chief scientific officer Dr Mark Bleackley said:

The resulting drug product, and supporting data, will form an important component of future regulatory filings and will facilitate Incannex's development of psilocybin-assisted psychotherapy for Generalised Anxiety Disorder.

This therapy has the potential to help millions of people whose lives are seriously impacted by severe anxiety and for whom current treatment options have not been effective.

Incannex share price snapshot

Cannabis shares are still a highly speculative segment of the share market.

This ASX 300 cannabis share is currently down 18% in the year to date, compared to a 5% bump for the S&P/ASX All Ordinaries Index (ASX: XAO).

Over the past 12 months, Incannex shares are down 78%. Over the past five years, they are up 635%.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »